PMID- 31993889
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20220414
IS  - 1434-9949 (Electronic)
IS  - 0770-3198 (Linking)
VI  - 39
IP  - 6
DP  - 2020 Jun
TI  - HDL cholesterol efflux capacity is related to disease activity in psoriatic 
      arthritis patients.
PG  - 1871-1880
LID - 10.1007/s10067-020-04961-4 [doi]
AB  - OBJECTIVE: Cholesterol efflux capacity (CEC) is the ability of high-density 
      lipoprotein (HDL) cholesterol to accept cholesterol from macrophages. CEC is 
      linked to cardiovascular events in the general population, and it has been shown 
      to be disrupted in inflammatory states. The aim of this study was to establish 
      whether CEC is impaired in PsA patients and if this could be explained by 
      disease-related features like disease activity. METHODS: Case-control study that 
      encompassed 105 individuals: 52 PsA patients and 53 controls. CEC, using an in 
      vitro assay, and lipoprotein serum concentrations were assessed in patients and 
      controls. Disease activity in patients with PsA was measured using the Disease 
      Activity Index for Psoriatic Arthritis (DAPSA). Multivariate analysis was 
      performed to study the differences between CEC in patients and controls, and the 
      relation of CEC with PsA activity-related data and lipid profile. RESULTS: Total 
      cholesterol, apolipoprotein A1, and LDL cholesterol serum levels were 
      downregulated in PsA patients. CEC did not differ between controls and patients 
      (17 +/- 10 vs. 18 +/- 2%, p = 0.15) after adjusting for traditional cardiovascular 
      risk factors or other variations in the lipid profile related to the disease. 
      Traditional cardiovascular risk factors, both in patients and controls, were not 
      related to CEC. After multivariate regression analysis, the DAPSA score was 
      inversely and independently associated with CEC (beta coefficient - 0.75 [95%CI 
      - 1.39-- 0.11] %, p = 0.023). CONCLUSION: CEC is inversely associated with 
      disease activity in PSA patients, reinforcing the role of disease activity as a 
      key factor in the development of accelerated atherosclerosis in these 
      patients.Key Points* Cholesterol efflux capacity is linked to cardiovascular 
      events in the general population.* In patients with psoriatic arthritis, 
      cholesterol efflux capacity is inversely associated with disease activity (beta 
      coefficient - 0.75[95% CI - 1.39-- 0.11] %, p = 0.023).* This finding reinforces 
      the role of disease activity as a key factor in increasing cardiovascular risk in 
      psoriatic arthritis patients.
FAU - Ferraz-Amaro, Ivan
AU  - Ferraz-Amaro I
AUID- ORCID: 0000-0003-0197-5267
AD  - Servicio de Reumatologia, Hospital Universitario de Canarias, La Laguna, Spain.
FAU - Hernandez-Hernandez, Maria Vanesa
AU  - Hernandez-Hernandez MV
AD  - Servicio de Reumatologia, Hospital Universitario de Canarias, La Laguna, Spain.
FAU - Armas-Gonzalez, Estefania
AU  - Armas-Gonzalez E
AD  - Servicio de Reumatologia, Hospital Universitario de Canarias, La Laguna, Spain.
FAU - Sanchez-Perez, Hiurma
AU  - Sanchez-Perez H
AD  - Servicio de Reumatologia, Hospital Universitario de Canarias, La Laguna, Spain.
FAU - Machado, Jose David
AU  - Machado JD
AD  - Departamento de Farmacologia, Facultad de Medicina, Universidad de La Laguna, La 
      Laguna, Spain.
FAU - Diaz-Gonzalez, Federico
AU  - Diaz-Gonzalez F
AUID- ORCID: 0000-0002-4139-9295
AD  - Servicio de Reumatologia, Hospital Universitario de Canarias, La Laguna, Spain. 
      federico.diaz.gonzalez@gmail.com.
AD  - Departamento de Medicina Interna, Dermatologia y Psiquiatria, Facultad de 
      Medicina, Universidad de La Laguna, La Laguna, Spain. 
      federico.diaz.gonzalez@gmail.com.
AD  - Division of Rheumatology, Hospital Universitario de Canarias, 38320, Santa Cruz 
      de Tenerife, Spain. federico.diaz.gonzalez@gmail.com.
LA  - eng
GR  - PI15/01810/Instituto de Salud Carlos III/
GR  - PI17/00083/Instituto de Salud Carlos III/
PT  - Journal Article
DEP - 20200128
PL  - Germany
TA  - Clin Rheumatol
JT  - Clinical rheumatology
JID - 8211469
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Lipids)
RN  - 97C5T2UQ7J (Cholesterol)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arthritis, Psoriatic/*metabolism
MH  - Case-Control Studies
MH  - Cholesterol/*metabolism
MH  - Cholesterol, HDL/*metabolism
MH  - Down-Regulation
MH  - Female
MH  - Humans
MH  - Linear Models
MH  - Lipids/blood
MH  - Macrophages/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Plaque, Atherosclerotic/metabolism
OTO - NOTNLM
OT  - Cholesterol efflux capacity
OT  - Disease activity
OT  - Dyslipidemia
OT  - Psoriatic arthritis
EDAT- 2020/01/30 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/01/30 06:00
PHST- 2019/12/14 00:00 [received]
PHST- 2020/01/24 00:00 [accepted]
PHST- 2020/01/22 00:00 [revised]
PHST- 2020/01/30 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
PHST- 2020/01/30 06:00 [entrez]
AID - 10.1007/s10067-020-04961-4 [pii]
AID - 10.1007/s10067-020-04961-4 [doi]
PST - ppublish
SO  - Clin Rheumatol. 2020 Jun;39(6):1871-1880. doi: 10.1007/s10067-020-04961-4. Epub 
      2020 Jan 28.